In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A nationwide target trial emulation in US veterans with type 2 diabetes found that semaglutide initiation was associated with a twofold increased risk of nonarteritic anterior ischemic optic neuropathy...
An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...
A large observational cohort study published in Annals of Internal Medicine examined the effectiveness of statin therapy for primary prevention in adults with type 2 diabetes stratified by predicted 10-year...
A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...
A multicenter trial conducted in China found that an artificial intelligence–based insulin clinical decision support system provided glycemic outcomes comparable to standard therapy administered by senior...
